TAK 071

Drug Profile

TAK 071

Alternative Names: TAK-071

Latest Information Update: 12 Apr 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Takeda
  • Class Antidementias; Nootropics
  • Mechanism of Action Muscarinic M1 receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Alzheimer's disease

Most Recent Events

  • 27 Mar 2018 Takeda terminates a phase I trial as data from cohort was no longer needed due to indication change in Alzheimer's disease in USA (PO) (NCT02769065)
  • 27 Mar 2018 Takeda terminates a phase Ib pharmacodynamic trial prematurely due to indication change in Healthy volunteers in USA (PO) (NCT02918266)
  • 16 Jul 2017 Pharmacodynamics data from a preclinical trial in Alzheimer's disease presented at the Alzheimer's Association International Conference (AAIC-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top